| 02/07/25 | 10:00:00 | 2 Jul 2025 | | Update on Joint Corporate Brokers in London | RNS |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | China Approval based on Phase III SACHI Trial | RNS |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | Total Voting Rights | RNS |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | Blocklisting Six Monthly Return | RNS |
| 10/06/25 | 11:00:01 | 10 Jun 2025 | | Grant of Share Options and Awards under LTIP | RNS |
| 05/06/25 | 07:00:19 | 5 Jun 2025 | | HUTCHMED and Innovent Announce NDA Acceptance | RNS |
| 02/06/25 | 07:00:14 | 2 Jun 2025 | | HUTCHMED Highlights SACHI Phase III Data at ASCO | RNS |
| 30/05/25 | 09:30:01 | 30 May 2025 | | Total Voting Rights | RNS |
| 23/05/25 | 07:00:09 | 23 May 2025 | | HUTCHMED Highlights Data to be Presented at ASCO | RNS |
| 13/05/25 | 11:45:00 | 13 May 2025 | | AGM held on May 13, 2025 – Poll Results | RNS |
| 24/04/25 | 07:00:13 | 24 Apr 2025 | | HUTCHMED - Data to be Presented at AACR 2025 | RNS |
| 22/04/25 | 07:00:15 | 22 Apr 2025 | | HUTCHMED Completes Enrollment of Phase II Study | RNS |
| 07/04/25 | 09:30:00 | 7 Apr 2025 | | 2024 Annual Report and Notice of AGM | RNS |
| 31/03/25 | 10:30:00 | 31 Mar 2025 | | Extraordinary General Meeting – Poll Results | RNS |
| 21/03/25 | 10:00:01 | 21 Mar 2025 | | NMPA Conditional Approval for TAZVERIK® | RNS |
| 20/03/25 | 09:30:01 | 20 Mar 2025 | | Retirement of Independent Non-executive Directors | RNS |
| 20/03/25 | 07:00:13 | 20 Mar 2025 | | HUTCHMED Highlights Savolitinib SAVANNAH Phase II | RNS |
| 19/03/25 | 13:45:00 | 19 Mar 2025 | | Publication of Form 20-F | RNS |
| 19/03/25 | 11:00:00 | 19 Mar 2025 | | 2024 Final Results and Business Updates | RNS |
| 19/03/25 | 07:00:12 | 19 Mar 2025 | | Phase II/III Study of Fruquintinib and Sintilimab | RNS |
| 14/03/25 | 09:30:00 | 14 Mar 2025 | | Adoption of the 2025 Long Term Incentive Plan | RNS |
| 14/03/25 | 09:30:00 | 14 Mar 2025 | | Vesting of awards under Long Term Incentive Plan | RNS |
| 13/03/25 | 09:30:00 | 13 Mar 2025 | | Notice of Extraordinary General Meeting | RNS |
| 06/03/25 | 10:00:00 | 6 Mar 2025 | | Completed Enrollment of Phase II Study | RNS |
| 05/03/25 | 10:00:00 | 5 Mar 2025 | | Directorate Change | RNS |
| 03/03/25 | 07:00:10 | 3 Mar 2025 | | Overseas Regulatory Announcement | RNS |
| 28/02/25 | 15:00:01 | 28 Feb 2025 | | Overseas Regulatory Announcement | RNS |
| 19/02/25 | 08:30:01 | 19 Feb 2025 | | Notice of Results | RNS |
| 28/01/25 | 09:00:00 | 28 Jan 2025 | | Overseas Regulatory Announcement | RNS |
| 14/01/25 | 07:00:07 | 14 Jan 2025 | | Full Approval for ORPATHYS in China | RNS |
| 02/01/25 | 07:01:00 | 2 Jan 2025 | | China NDA Acceptance for ORPATHYS and TAGRISSO | RNS |
| 02/01/25 | 07:00:07 | 2 Jan 2025 | | Overseas Regulatory Announcement | RNS |
| 02/01/25 | 07:00:05 | 2 Jan 2025 | | US$608m Divestment of Non-Core Joint Venture | RNS |
| 31/12/24 | 08:30:01 | 31 Dec 2024 | | Appointment of Joint Corporate Broker | RNS |
| 30/12/24 | 08:30:00 | 30 Dec 2024 | | Blocklisting Six Monthly Return | RNS |
| 13/12/24 | 07:00:07 | 13 Dec 2024 | | HUTCHMED to Receive Milestone Payment from Takeda | RNS |
| 12/12/24 | 07:00:08 | 12 Dec 2024 | | Breakthrough Therapy Designation in China | RNS |
| 03/12/24 | 10:00:00 | 3 Dec 2024 | | HUTCHMED and Innovent Announce ELUNATE Approval | RNS |
| 29/11/24 | 08:30:00 | 29 Nov 2024 | | Total Voting Rights | RNS |
| 28/11/24 | 10:32:34 | 28 Nov 2024 | | Continued Inclusion of ORPATHYS in China NRDL | RNS |
| 22/11/24 | 07:00:10 | 22 Nov 2024 | | FRUZAQLA® Launched in Japan by Takeda | RNS |
| 20/11/24 | 09:30:00 | 20 Nov 2024 | | Appointment of Independent Non-executive Director | RNS |
| 06/11/24 | 07:00:08 | 6 Nov 2024 | | Clinical Data to be Presented at ASH and ESMO Asia | RNS |
| 31/10/24 | 08:30:01 | 31 Oct 2024 | | First Commercial Milestone Payment | RNS |
| 31/10/24 | 08:30:01 | 31 Oct 2024 | | Total Voting Rights | RNS |
| 21/10/24 | 09:30:01 | 21 Oct 2024 | | Vesting of awards under the LTIP | RNS |
| 16/10/24 | 07:00:06 | 16 Oct 2024 | | SAVANNAH: clinically meaningful response rate | RNS |
| 24/09/24 | 08:00:00 | 24 Sept 2024 | | Japan Approval for FRUZAQLA | RNS |
| 09/09/24 | 07:00:10 | 9 Sept 2024 | | Clinical Data to be Presented at ESMO and WCLC | RNS |
| 30/08/24 | 09:30:00 | 30 Aug 2024 | | Total Voting Rights | RNS |
